Genmab — Marts 2017
-
Amerikansk biotekselskab stiger efter ny stor BMS-aftale
En stor partneraftale med medicinalkæmpen Bristol-Myers Squibb ser ud til at give et amerikansk biotekselskab et godt løft på børsen.
(medwatch.dk)
-
-
Apropos NICE og kombinationerne så har de et stykke tid arbejdet "To appraise the clinical and cost effectiveness of daratumumab with
lenalidomide and dexamethasone, and daratumumab with bortezomib and
dexamethasone, within its marketing authorisation for treating relapsed or
refractory multiple myeloma. https://www.nice.org.uk/guidance/indevelopment/gid-ta10104 -
1448 her?
-
21.000 til A/B i auktionen.
-
-
Har dette link om NICE været bragt før? http://www.fiercepharma.com/pharma/j-j-s-darzalex-gets-cold-shoulder-from-nice-multiple-myeloma
-
Jeg vil bede Rachel om at uddybe problematikken
-
i morgen ved præsentationen på InvestorDagen.
-
Helge - kommer du og Rachel på video på InvestorDagen? Hvis ja, så må du gerne linke indslaget hertil.
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind